Identification of candidate genes for human retinal degeneration loci using differentially expressed genes from mouse photoreceptor dystrophy models.
OBJECTIVE
Retinal degeneration (RD) is a complex mechanism that appears to involve many biologic processes including oxidative stress, apoptosis, and cellular remodeling. Currently there are 51 mapped, but not identified, RD human disease loci.


METHODS
To assign possible disease genes to RD loci, we have used a comparative genomics procedure that incorporates microarray gene expression data of three independent mouse models for photoreceptor dystrophy (rd1, rd2, and constant light-damage in BALB/c mice), human ortholog data, and databases of known chromosomal locations involved in human RD. Immunohistochemistry and enzyme activity assays were used to further characterize a candidate gene product.


RESULTS
Our analysis yielded candidate genes for four mapped, but unsolved, human chromosomal locations and confirmed two previously identified monogenic disease loci for human RD, thus validating our approach. PLA2G7 (phospholipase A2, group VII; PAF-AH, Lp-PLA2), a candidate for a dominant form macular dystrophy (Benign Concentric Annular Macular Dystrophy [BCMAD]), was selected for further study. The PLA2G7 enzyme is known to mediate breakdown of oxidatively damaged phospholipids, a contributor to oxidative stress in the retina. PLA2G7 protein was enriched in mouse photoreceptor inner and outer segments. In the rd1, rd2, and BALB/c mice exposed to constant light, retinal tissue activity levels, but not plasma levels, were significantly reduced at the onset of photoreceptor cell death.


CONCLUSIONS
We have shown that this comparative genomics approach verified existing RD genes as well as identified novel RD candidate genes. The results on the characterization of the PLA2G7 protein, one of the novel RD genes, suggests that retinal tissue PLA2G7 levels may constitute an important risk factor for BCMAD. In summary, this reverse mapping approach, using accepted mouse models of human disease and known human RD loci, may prove useful in identifying possible novel disease candidates for RD and may be applicable to other human diseases.
Demos
Christina
C
Department of Physiology and Neuroscience, Medical University of South Carolina, Charleston, SC 29425, USA.
Bandyopadhyay
Mausumi
M
Rohrer
Bärbel
B
D000818:Animals; D004195:Disease Models, Animal; D015536:Down-Regulation; D020869:Gene Expression Profiling; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D054467:Phospholipases A2 / Q000235:genetics / Q000378:metabolism; D020419:Photoreceptor Cells, Vertebrate / Q000473:pathology*; D021381:Protein Transport; D012162:Retinal Degeneration / Q000201:enzymology / Q000235:genetics*; D015854:Up-Regulation
D054467:Phospholipases A2
Science. 2005 Apr 15;308(5720):419-21
15761120
Nat Genet. 2004 Nov;36(11):1153-8
15514669
Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1293-301
16565360
Ann N Y Acad Sci. 1999;893:282-5
10672249
J Neurosci. 1999 Oct 15;19(20):8919-30
10516311
Nature. 1989 Mar 2;338(6210):70-3
2918924
Arch Ophthalmol. 2004 Apr;122(4):598-614
15078679
Invest Ophthalmol Vis Sci. 2004 Aug;45(8):2737-46
15277499
Exp Eye Res. 2006 Aug;83(2):380-9
16626700
Science. 1974 Nov 1;186(4162):449-51
4369896
Prog Retin Eye Res. 2001 Nov;20(6):705-32
11587915
Neuron. 1991 Jan;6(1):61-70
1986774
Science. 2005 Apr 15;308(5720):421-4
15761121
Hum Mol Genet. 2008 May 1;17(9):1318-28
18204052
Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):974-8
8302876
Invest Ophthalmol Vis Sci. 2004 Apr;45(4):1247-58
15037594
Invest Ophthalmol Vis Sci. 2003 May;44(5):2211-20
12714663
Invest Ophthalmol Vis Sci. 1995 Feb;36(2):263-75
7843898
Science. 2005 Apr 15;308(5720):385-9
15761122
BMC Genomics. 2004 Jul 29;5(1):50
15283859
Clin Exp Ophthalmol. 2007 Jul;35(5):473-85
17651254
Exp Eye Res. 2003 Jan;76(1):125-9
12589782
PLoS Biol. 2004 Sep;2(9):E247
15226823
J Immunol. 2006 Aug 1;177(3):1872-8
16849499
Curr Atheroscler Rep. 2007 Aug;9(2):97-103
17877917
N Engl J Med. 2007 Aug 9;357(6):553-61
17634448
Invest Ophthalmol Vis Sci. 2003 Apr;44(4):1426-34
12657576
Curr Opin Genet Dev. 1994 Jun;4(3):427-38
7919921
Biostatistics. 2003 Jul;4(3):465-77
12925512
J Neurosci. 2005 May 4;25(18):4540-9
15872101
Exp Eye Res. 2007 Jan;84(1):82-91
17069800
Novartis Found Symp. 2004;255:17-27; discussion 27-36, 177-8
14750594
Invest Ophthalmol Vis Sci. 2005 Jan;46(1):349-57
15623795
Nat Genet. 2006 Apr;38(4):458-62
16518403
Eur J Hum Genet. 2003 May;11(5):420-3
12734549
Clin Immunol. 2003 Jun;107(3):140-51
12804527
J Biol Chem. 2004 Oct 1;279(40):41903-10
15218024
FASEB J. 2005 Oct;19(12):1683-5
16099945
J Clin Endocrinol Metab. 2005 May;90(5):3100-5
15713711
Hum Genet. 2005 Dec;118(3-4):356-65
16189710
Am J Hum Genet. 2000 May;66(5):1522-30
10733466
Curr Opin Lipidol. 2008 Jun;19(3):289-94
18460921
Mol Vis. 2007 Feb 28;13:287-92
17356515
Bioessays. 2001 Jul;23(7):605-18
11462214
J Biol Chem. 1987 Mar 25;262(9):4223-30
3558407
Semin Immunol. 1998 Oct;10(5):355-61
9799710